MedTech Global Insights

US DHT Trials: FDA's Hidden Rules | A Pure Global Brief

13 Dec 2025

Audio

Description

In this episode of MedTech Global Insights, we dissect the FDA's newly finalized guidance on using Digital Health Technologies (DHTs) for remote data collection in clinical trials. This pivotal update opens the door for more decentralized and patient-centric studies but introduces stringent new requirements for verification, validation, and data integrity that will reshape how MedTech companies approach clinical research. We explore what the "fit-for-purpose" standard truly means for companies hoping to leverage consumer wearables and sensors. We also uncover the significant operational challenges, from ensuring data consistency across different device models to meeting cybersecurity and electronic record standards. This is a must-listen for regulatory affairs professionals, clinical trial managers, and product developers in the MedTech space who need to understand the new rules of the road for digital evidence generation. A key challenge highlighted is the use of a popular smartwatch to monitor patient vitals in a pivotal drug or device trial. Under the new guidance, the company can no longer assume the device's commercial-grade data is sufficient. They must now fund and execute a separate validation study to prove its clinical accuracy and reliability for the specific patient population and indication. A failure to provide this evidence could lead to the rejection of the entire clinical trial dataset by the FDA, costing millions and delaying market access. What You'll Learn: 1. What are the most significant differences between the FDA's draft and final guidance on DHTs? 2. How do you prove a consumer wearable is "fit-for-purpose" for a clinical trial endpoint? 3. What are the new requirements for using different models or brands of a DHT in a single study? 4. Which specific data integrity and cybersecurity risks must now be addressed? 5. How does this FDA guidance impact your global regulatory strategy for Europe and Asia? 6. What level of software and hardware validation does the FDA now expect? 7. How can you ensure patient privacy and data security meet the new standards? 8. What kind of documentation is needed for a successful regulatory submission involving DHT data? For more information, contact us at [email protected] or visit https://pureglobal.com/. For FREE AI tools and a comprehensive medical device database, visit https://pureglobal.ai/.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes

🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Other recent transcribed episodes

Transcribed and ready to explore now

13:00H | 21 DIC 2025 | Fin de Semana

01 Jan 1970

Fin de Semana

10:00H | 21 DIC 2025 | Fin de Semana

01 Jan 1970

Fin de Semana

12:00H | 20 DIC 2025 | Fin de Semana

01 Jan 1970

Fin de Semana

2ª PARTE | 06 ENE 2026 | EL PARTIDAZO DE COPE

01 Jan 1970

El Partidazo de COPE

3ª PARTE | 22 ENE 2026 | EL PARTIDAZO DE COPE

01 Jan 1970

El Partidazo de COPE

3ª PARTE | 04 MAR 2026 | EL PARTIDAZO DE COPE

01 Jan 1970

El Partidazo de COPE

Comments

There are no comments yet.

Please log in to write the first comment.

Report any issue

MedTech Global Insights

US DHT Trials: FDA's Hidden Rules | A Pure Global Brief

This episode hasn't been transcribed yet

Other recent transcribed episodes

13:00H | 21 DIC 2025 | Fin de Semana

10:00H | 21 DIC 2025 | Fin de Semana

12:00H | 20 DIC 2025 | Fin de Semana

2ª PARTE | 06 ENE 2026 | EL PARTIDAZO DE COPE

3ª PARTE | 22 ENE 2026 | EL PARTIDAZO DE COPE

3ª PARTE | 04 MAR 2026 | EL PARTIDAZO DE COPE

Sign in to Audioscrape

Share this moment